Nyxoah
NYXH | NASDAQ
$0.89
-$0.01 (-1.06%)
At close: Nov 16, 2026, 4:00 PM ET
$0.89
$0.00 (+0.42%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-1.06%
(1D)No price chart data available for 1D timeframe.
Rating
44.2
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #414/1021 (Top 41%)
Key Statistics
Market Data
Market Cap $91.01M
1D Range
0.88 0.90
52W Range
0.81 5.23
Valuation (TTM)
PE -0.45
PB 1.18
EV/EBITDA -0.84
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $3.00
Cash Flow
FCF Yield -90.4%
SBC Adj. FCF Yield -93.1%
SBC Impact -3.0%
Margins
Gross Margin 54.3%
Operating Margin -282.9%
FCF Margin -250.6%
Growth (CAGR)
Revenue 3Y | 5Y 98.3% |
119.0%
Dil EPS 3Y | 5Y 0.3% |
-12.8%
FCF 3Y | 5Y -14.9% |
-13.5%
Returns
ROA -62.4%
ROE -157.0%
ROIC -68.1%
Financial Health
Net Cash
€25.17M ($28.51M)
Current Ratio 2.19
Interest Coverage -4.86
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric,...
Sector Healthcare
Industry Medical - Specialties
Employees 154
IPO Date Apr 28, 2021
Website www.nyxoah.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.2
Beat +16.67%
YoY:
+72.97% REV
$10.39M
Miss -9.19%
YoY:
+349.76%Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$3.00
Upside
+237.08%
Buy (2)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NYXH